Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis, Inc. (symbol: PSNL) is a leading genome-scale diagnostics company dedicated to advancing the field of genome-guided medicine. The company's mission is to extract the most accurate genetic data from each sample and draw reliable, medically-focused conclusions. Personalis leverages cutting-edge whole genome and exome sequencing techniques, conducted in their state-of-the-art laboratory, to provide comprehensive insights.
Personalis offers a range of products and services designed to support academic, pharmaceutical, and biotech researchers. Their flagship products include ImmunoID NeXT, NeXT Personal, and NeXT Dx Test, which cater to diverse needs including personalized cancer vaccines and next-generation cancer immunotherapies. Additionally, their solutions serve those engaged in large case-control and family-based genome studies of complex or Mendelian diseases, pharmacogenomics, and cancer research.
Their proprietary databases, advanced human reference sequences, and sophisticated algorithms ensure accurate and comprehensive end-to-end human genome sequencing and analysis. Personalis' commitment to quality and innovation positions them as a critical player in the evolving landscape of genomic medicine.
Recent achievements include partnerships with key pharmaceutical companies to enhance the development of personalized cancer treatments. The company continues to innovate and expand its service offerings, ensuring researchers and clinicians have access to the most advanced tools for genomic analysis.
For those seeking the latest updates and relevant information on Personalis, Inc., StockTitan provides a comprehensive list of news and developments, ensuring investors and stakeholders stay informed on this pioneering company's performance and advancements.
Personalis, Inc. (PSNL) and Moderna, Inc. (MRNA) have signed a new agreement to utilize the Personalis NeXT Platform for clinical studies involving the investigational personalized cancer vaccine, mRNA-4157/V940. This platform previously supported the Phase 2b clinical study, sequencing genomic data from patient tumor samples to identify mutations that may prompt tailored antitumor responses. Chris Hall from Personalis expressed excitement about continuing their collaboration with Moderna, emphasizing the aim to advance individualized cancer treatments.
Personalis, Inc. (NASDAQ: PSNL) reported preliminary fourth-quarter revenue of approximately $16.7 million and full-year revenue of $65.0 million for 2022, surpassing previous guidance of $63.0 to $64.0 million. Key highlights include a 42% increase in revenue from biopharma and other customers, totaling $56.6 million for the year. The U.S. Department of Veterans Affairs Million Veterans Program revenue dropped to $0.9 million in Q4, down 82% year-over-year. Cash and short-term investments amounted to $167.0 million as of December 31, 2022.
Personalis, Inc. (Nasdaq: PSNL) announced the grant of non-qualified stock options for 35,000 shares and restricted stock units (RSUs) covering 42,100 shares to three new employees between December 5, 2022, and December 16, 2022. The grant is part of the 2020 Inducement Plan, aimed at attracting new talent to the company. The options have an exercise price of $2.83 and vest over four years. This decision aligns with Nasdaq regulations and reflects Personalis' commitment to enhancing its workforce as a leader in cancer genomics.
Personalis, Inc. (NASDAQ: PSNL) announced the retirement of CEO John West, effective December 31, 2022. West, a co-founder, has led the company since its inception in 2011, focusing on advanced cancer genomics. Aaron Tachibana, currently CFO, will serve as interim CEO, and Christopher Hall will be promoted to President. The board will search for a permanent CEO. West expressed pride in the company’s accomplishments in enhancing cancer treatments and genomic profiling.
Personalis, Inc. (NASDAQ: PSNL) has announced a collaboration with UC San Francisco (UCSF) to deploy a personalized liquid biopsy-based research assay for colorectal cancer. The NeXT Personal™ assay will evaluate ctDNA signatures linked to treatment response in late-stage patients undergoing therapy with capecitabine, pembrolizumab, and bevacizumab. This partnership aims to enhance early detection of treatment response and disease recurrence, addressing the limitations of current ctDNA assays.
Personalis, Inc. (NASDAQ: PSNL) announced it will present data from its NeXT Platform® at the Society for Immunotherapy of Cancer (SITC) Annual Meeting from November 8-12 in Boston. The presentation includes three abstracts that demonstrate advancements in next-generation sequencing (NGS) related to immuno-oncology. Key highlights include improved neoantigen prediction and the integration of immune infiltration metrics to enhance response predictions for immunotherapy treatments. The data aims to improve patient stratification and therapeutic efficacy.
Personalis, Inc. (Nasdaq: PSNL) reported third-quarter financial results for 2022, showing revenues of $14.9 million, down from $22.3 million in Q3 2021. Notably, revenue from biopharma customers increased by 73% to $14.9 million, driven by a $7.4 million contribution from Natera. The company announced collaborations with BC Cancer and Duke University to enhance cancer detection methods. However, net loss for the quarter was $26.5 million with a gross margin of 16.7%. The outlook for 2022 projects total revenue between $63 million and $64 million, with net loss expected between $111 million and $114 million.
Personalis, Inc. (NASDAQ: PSNL) has appointed Christopher Hall as SVP and Head of Diagnostics Business to enhance its commercial strategy. Hall joins with over 20 years in diagnostics, previously serving as CEO of Naring Health and holding executive roles at Veracyte. His past achievements include scaling Veracyte's diagnostic revenue to nearly $100 million. To facilitate his role, Personalis granted him inducement awards consisting of stock options and restricted stock units covering 500,000 shares, vesting over four years at an exercise price of $2.67 per share.
Personalis, Inc. (Nasdaq: PSNL) will release its Q3 2022 financial results on November 2, 2022. The company will host a conference call that day at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results and recent highlights. Interested parties can register for the call in advance, and a live webinar will be available on the company's website. Personalis is focused on advanced genomics for precision oncology, providing insights into cancer therapies and diagnostics through its NeXT Platform, which analyzes all human genes from a single sample.
Personalis, Inc. (NASDAQ: PSNL) has partnered with Duke University and Olink Proteomics AB to research the effects of immunotherapy on advanced gastroesophageal cancer. The collaboration aims to identify composite biomarkers to enhance therapeutic decision-making. Gastroesophageal cancer is prevalent, with nearly 50% of patients facing advanced stages at diagnosis. Key goals include understanding responses to pembrolizumab, an approved immunotherapy, and developing strategies to optimize treatment effectiveness. The study will leverage Personalis' cutting-edge technology for comprehensive tumor profiling.
FAQ
What is the current stock price of Personalis (PSNL)?
What is the market cap of Personalis (PSNL)?
What does Personalis, Inc. specialize in?
What are Personalis' main products?
Who can benefit from Personalis' services?
What technologies does Personalis use?
What is the mission of Personalis, Inc.?
How does Personalis support cancer research?
What recent achievements has Personalis made?
What sets Personalis apart from other genomic companies?
Why is genome sequencing important in medical research?
How can I stay updated on Personalis' latest news?
